Monitor the progress of the Business Combination with Westin Acquisition Corp. and the SEC's review of the Form F-4 registration statement, as these are critical conditions to closing. The stock is thinly traded on the OTC market, so any news on the de-SPAC timeline or ELOC facility could drive outsized moves. The 120-day outside date (Nov 19, 2026) is the next key deadline.
Price Chart
Executive Summary
First Choice Healthcare Solutions (FCHS) entered into an Amended and Restated Stock Purchase Agreement to acquire Pointe Medical Services, Pointe Med Pharmacy, Livewell MD, and Live Well Drugstore (Trulife Pharmacy) from Dr. Gary C. Bernard for a maximum purchase price of $21.3 million. The acquisition is contingent on the consummation of a separate Business Combination with Westin Acquisition Corp., which will become the publicly traded parent (PubCo), and the availability of a $100 million equity line of credit (ELOC). The deal is not yet closed and faces significant execution risk given the interlocking conditions and the company's small-cap status on the OTC market.
Key Financial Metrics
Key Facts
- FCHS entered an Amended and Restated Stock Purchase Agreement to acquire four healthcare entities from Dr. Gary C. Bernard for a maximum of $21,306,000.
- The purchase price consists of $10.0M cash, ~$4.306M assumed debt, $6.0M in PubCo common stock, and a $1.0M contingent performance bonus.
- The acquisition closing is conditioned on the consummation of a Business Combination with Westin Acquisition Corp. and the availability of a $100M ELOC facility.
- The deal has an outside closing date of 120 days from July 22, 2026, extendable to 180 days if the F-4 registration statement remains under SEC review.
- The Stock Purchase Agreement amends and restates a prior 2023 agreement, and a $200,000 non-refundable advance has already been paid to the seller.
Financial Impact
Maximum purchase price of $21,306,000, comprising $10.0M cash (net of $300K advances), ~$4.306M assumed debt, $6.0M in PubCo stock, and a $1.0M contingent EBITDA-based bonus.
Risk Factors
- The acquisition is contingent on the Business Combination closing, which itself is subject to regulatory and financing conditions — failure of either kills the deal.
- The $3.0M deferred cash payment is tied to the effectiveness of the ELOC registration statement, creating a circular dependency.
- The company must repay the ~$4.3M assumed debt within 120 days of closing, which could strain liquidity if the ELOC is not available.
- The stock trades on OTC with low liquidity, amplifying price sensitivity to binary deal outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-039089 |
| Document: 0001493152-26-039089-index-headers.html | 0001493152-26-039089 |
| Document: 0001493152-26-039089-index.html | 0001493152-26-039089 |
| Document: 0001493152-26-039089.txt | 0001493152-26-039089 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | 8-K | $0.009000 | awaiting T+60 | — | $0.008000 (−11.11%) |
Jul 28, 2026 12w ago | 8-K | $0.009000 $0.008000 | ▼ −11.11% | ▼ −17.36% | $0.008000 (−11.11%) |
Apr 14, 2026 27w ago | S-1/A | $0.004000 $0.004000 | · 0.00% | ▲ +8.52% | $0.008000 (−100.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers